|
TSHA | Taysha Gene Therapies, Inc. |
|
|
TSHA | Taysha Gene Therapies, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.24 |
| Leverage | 30.82% |
| Market Cap | $ 916.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -99.6m |
| Margin | -1666.11% |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.